Update of the human parvovirus B19 biology

Transfusion Clinique et Biologique

Volumn 23, Issue 1, 2016, Pages 5-12

  Servant Delmas, A ^a   Morinet, F ^b  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Blood transfusion; Genetic diversity; Parvovirus B19; Persistent infection; Replication

Indexed keywords

VIRUS DNA;

ARTICLE; BLOOD TRANSFUSION; DISEASE ASSOCIATION; DNA SEQUENCE; ERYTHEMA INFECTIOSUM; ERYTHROBLASTOPENIA; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN PARVOVIRUS B19; INFECTIOUS DOSE; MICROBIOLOGY; NONHUMAN; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; ADVERSE EFFECTS; BLOOD SAFETY; CELL HYPOXIA; CLASSIFICATION; GENETIC VARIATION; GENETICS; ISOLATION AND PURIFICATION; PARVOVIRIDAE INFECTIONS; PHYSIOLOGY; TRANSMISSION; VIREMIA; VIROLOGY;

BLOOD SAFETY; BLOOD TRANSFUSION; CELL HYPOXIA; DNA, VIRAL; GENETIC VARIATION; GENOTYPE; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; VIREMIA; VIRUS REPLICATION;

EID: 84958160419     PISSN: 12467820     EISSN: 19538022     Source Type: Journal    
DOI: 10.1016/j.tracli.2015.11.006     Document Type: Article

References (92)

1. Cossart Y.E., Field A.M., Cant B., Widdows D. Parvovirus-like particles in human sera. Lancet 1975, 1:72-73.
2. Pattison J.R. B19 virus-pathogenic human parvovirus. Blood Rev 1987, 1:58-64.
3. Anderson M.J. Human parvovirus infections. J Virol Methods 1987, 17:175-181.
4. Cotmore S.F., Tattersall P. Characterization and molecular cloning of a human parvovirus genome. Science 1984, 226:1161-1165.
5. Brown K.E., Anderson S.M., Young N.S. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993, 262:114-117.
6. Morinet F., Parent M., Bergeron C., Pillet S., Capron C. Oxygen and viruses: a breathing story. J Gen Virol 2015, 96:1979-1982.
7. Kurtzman G.J., Cohen B.J., Field A.M., Oseas R., Blaese R.M., Young N.S. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989, 84:1114-1123.
8. Servant-Delmas A., Lefrere J.J., Morinet F., Pillet S. Advances in human B19 erythrovirus biology. J Virol 2010, 84:9658-9665.
9. Rodriguez Bandera A.I., Mayor Arenal M., Vorlicka K., Ruiz Bravo-Burguilllos E., Montero Vega D., Vidaurrazaga Diaz-Arcaya C. Acute parvovirus B19 infection in adults: a retrospective study of 49 cases. Actas Dermosifiliogr 2015, 106:44-50.
10. Saed S., Weinstein Velez M., Tomecki K.J., Fernandez A.P. Parvovirus mimicking acute HIV infection. Cleve Clin J Med 2015, 82:481-482.
11. Kurtzman G., Frickhofen N., Kimball J., Jenkins D.W., Nienhuis A.W., Young N.S. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989, 321:519-523.
12. Marchand S., Tchernia G., Hiesse C., et al. Human parvovirus B19 infection in organ transplant recipients. Clin Transplant 1999, 13:17-24.
13. Subtil D., Garabedian C., Chauvet A. Parvovirus B19 infection and pregnancy. Presse Med 2015, 44:647-653.
14. Douvoyiannis M., Litman N., Goldman D.L. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis 2009, 48:1713-1723.
15. Bock C.T., Klingel K., Aberle S., et al. Human parvovirus B19: a new emerging pathogen of inflammatory cardiomyopathy. J Vet Med B Infect Dis Vet Public Health 2005, 52:340-343.
16. Saint-Martin J., Choulot J.J., Bonnaud E., Morinet F. Myocarditis caused by parvovirus. J Pediatr 1990, 116:1007-1008.
17. Parra D., Mekki Y., Durieu I., Broussolle C., Seve P. Clinical and biological manifestations in primary parvovirus B19 infection in immunocompetent adult: a retrospective study of 26 cases. Rev Med Interne 2014, 35:289-296.
18. Kishore J. Real time PCR reconfirmed three novel clinical associations of parvovirus B19: non-occlusive bowel gangrene, amegakaryocytic thrombocytopenia & myositis. Indian J Med Res 2015, 142:88-89.
19. Terrier B., Marie I., Lacraz A., et al. Non HCV-related infectious cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey and systematic review of the literature. J Autoimmun 2015, 10.1016/j.jaut.2015.08.008.
20. Page C., Hoffmann T.W., Benzerdjeb N., Desailloud R., Sevestre H., Duverlie G. Immunohistochemical- and PCR-based assay for the reproducible, routine detection of erythrovirus B19 in thyroid tissues. J Med Virol 2015, 87:1054-1059.
21. Wang L., Zhang W.P., Yao L., et al. PRDM1 expression via human parvovirus B19 infection plays a role in the pathogenesis of Hashimoto thyroiditis. Hum Pathol 2015, [In press].
22. Brown K.E. Human parvovirus B19 epidemiology and clinical manifestations. Human parvovirus B19 1997, 42-55. Karger, New York, [Vol. 20]. 1st ed. L.J. Anderson, N.S. Young (Eds.).
23. Young N.S., Brown K.E. Parvovirus B19. N Engl J Med 2004, 350:586-597.
24. Cassinotti P., Burtonboy G., Fopp M., Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997, 53:229-232.
25. Lundqvist A., Tolfvenstam T., Bostic J., Soderlund M., Broliden K. Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow. Scand J Infect Dis 1999, 31:11-16.
26. Nikkari S., Roivainen A., Hannonen P., et al. Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis 1995, 54:597-600.
27. Norja P., Hokynar K., Aaltonen L.M., et al. Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci U S A 2006, 103:7450-7453.
28. Lukashov V.V., Goudsmit J. Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses. J Virol 2001, 75:2729-2740.
29. Servant A., Laperche S., Lallemand F., et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002, 76:9124-9134.
30. Toan N.L., Duechting A., Kremsner P.G., et al. Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients. J Gen Virol 2006, 87:2941-2949.
31. Corcoran C., Hardie D., Yeats J., Smuts H. Genetic variants of human parvovirus B19 in South Africa: cocirculation of three genotypes and identification of a novel subtype of genotype 1. J Clin Microbiol 2009, 48:137-142.
32. Molenaar-de Backer M.W., Lukashov V.V., van Binnendijk R.S., Boot H.J., Zaaijer H.L. Global co-existence of two evolutionary lineages of parvovirus B19 1a, different in genome-wide synonymous positions. PLoS One 2012, 7:e43206.
33. Hokynar K., Soderlund-Venermo M., Pesonen M., et al. A new parvovirus genotype persistent in skin. Virology 2002, 302:224-228.
34. Nguyen Q.T., Wong S., Heegaard E.D., Brown K.E. Identification of a second novel human erythrovirus variant, A6. Virology 2002, 301:374-380.
35. Nguyen Q.T., Sifer C., Schneider V., Bernaudin F., Auguste V., Garbarg-Chenon A. Detection of an erythrovirus sequence distinct from B19 in a child with acute anemia. Lancet 1998, 352:1524.
36. Parsyan A., Szmaragd C., Allain J.P., Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J Gen Virol 2007, 88:428-431.
37. Kuhl U., Lassner D., Pauschinger M., et al. Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol 2008, 80:1243-1251.
38. Wong S., Young N.S., Brown K.E. Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia. J Infect Dis 2003, 187:1581-1586.
39. Sanabani S., Neto W.K., Pereira J., Sabino E.C. Sequence variability of human erythroviruses present in bone marrow of Brazilian patients with various parvovirus B19-related hematological symptoms. J Clin Microbiol 2006, 44:604-606.
40. Hokynar K., Norja P., Laitinen H., et al. Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests. J Clin Microbiol 2004, 42:2013-2019.
41. Candotti D., Etiz N., Parsyan A., Allain J.P. Identification and characterization of persistent human erythrovirus infection in blood donor samples. J Virol 2004, 78:12169-12178.
42. Hubschen J.M., Mihneva Z., Mentis A.F., et al. Phylogenetic analysis of human parvovirus B19 sequences from eleven different countries confirms the predominance of genotype 1 and suggests the spread of genotype 3b. J Clin Microbiol 2009, 10.1128/JCM.01201-09.
43. Schneider B., Hone A., Tolba R.H., Fischer H.P., Blumel J., Eis-Hubinger A.M. Simultaneous persistence of multiple genome variants of human parvovirus B19. J Gen Virol 2008, 89:164-176.
44. da Costa A.C., Bendit I., de Oliveira A.C., Kallas E.G., Sabino E.C., Sanabani S.S. Investigation of human parvovirus B19 occurrence and genetic variability in different leukaemia entities. Clin Microbiol Infect 2013, 19:E31-E43.
45. Cotmore S.F., Agbandje-McKenna M., Chiorini J.A., et al. The family Parvoviridae. Arch Virol 2014, 159:1239-1247.
46. Agbandje-McKenna M., Rossmann M.G. The structure of human parvovirus B19. Human parvovirus B19 1997, 3-15. Karger, New York, [Vol. 20]. 1st ed. L.J. Anderson, N.S. Young (Eds.).
47. Chipman P.R., Agbandje-McKenna M., Kajigaya S., et al. Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor. Proc Natl Acad Sci U S A 1996, 93:7502-7506.
48. Kaufmann B., Simpson A.A., Rossmann M.G. The structure of human parvovirus B19. Proc Natl Acad Sci U S A 2004, 101:11628-11633.
49. Zadori Z., Szelei J., Lacoste M.C., et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001, 1:291-302.
50. Brown K.E., Hibbs J.R., Gallinella G., et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994, 330:1192-1196.
51. Weigel-Van Aken K.A.K. Pharmacological activation of guanine nucleotide exchange factors for the small GTPase Rap1 recruits high affinity β1 integrins as co-receptors for parvovirus B19: improved ex vivo gene transfer to human erythroid progenitor cells. Hum Gene Ther 2009, 20:1665-1678.
52. Filippone C., Zhi N., Wong S., et al. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology 2008, 374:444-452.
53. Leisi R., von Nordheim M., Kempf C., Ros C. Specific targeting of proerythroblasts and erythroleukemic cells by the VP1u region of parvovirus B19. Bioconjug Chem 2015, 26:1923-1930.
54. Luo Y., Qiu J. Human parvovirus B19: a mechanistic overview of infection and DNA replication. Future Virol 2015, 10:155-167.
55. Guan W., Cheng F., Yoto Y., et al. Block to the production of full-length B19 virus transcripts by internal polyadenylation is overcome by replication of the viral genome. J Virol 2008, 82:9951-9963.
56. Pillet S., Le Guyader N., Hofer T., et al. Hypoxia enhances human B19 erythrovirus gene expression in primary erythroid cells. Virology 2004, 327:1-7.
57. Pillet S., Fichelson S., Morinet F., Young N.S., Zhi N., Wong S. Human B19 erythrovirus in vitro replication: what's new?. J Virol 2008, 82:8951-8953.
58. Chen A.Y., Guan W., Lou S., Liu Z., Kleiboeker S., Qiu J. Role of erythropoietin receptor signaling in parvovirus B19 replication in human erythroid progenitor cells. J Virol 2010, 84:12385-12396.
59. Luo Y., Lou S., Deng X., et al. Parvovirus B19 infection of human primary erythroid progenitor cells triggers ATR-Chk1 signaling, which promotes B19 virus replication. J Virol 2011, 85:8046-8055.
60. Zhi N., Zadori Z., Brown K.E., Tijssen P. Construction and sequencing of an infectious clone of the human parvovirus B19. Virology 2004, 318:142-152.
61. Guan W., Wong S., Zhi N., Qiu J. The genome of human parvovirus B19 can replicate in nonpermissive cells with the help of adenovirus genes and produces infectious virus. J Virol 2009, 83:9541-9553.
62. Winter K., von Kietzell K., Heilbronn R., Pozzuto T., Fechner H., Weger S. Roles of E4orf6 and VA I RNA in adenovirus-mediated stimulation of human parvovirus B19 DNA replication and structural gene expression. J Virol 2012, 86:5099-5109.
63. von Kietzell K., Pozzuto T., Heilbronn R., Grossl T., Fechner H., Weger S. Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q. J Virol 2014, 88:8102-8115.
64. Schmidt-Lucke C., Zobel T., Schrepfer S., et al. Impaired endothelial regeneration through human parvovirus B19-infected circulating angiogenic cells in patients with cardiomyopathy. J Infect Dis 2015, 212:1070-1081.
65. Cassinotti P., Schultze D., Schlageter P., Chevili S., Siegl G. Persistent human parvovirus B19 infection following an acute infection with meningitis in an immunocompetent patient. Eur J Clin Microbiol Infect Dis 1993, 12:701-704.
66. Dobec M., Juchler A., Flaviano A., Kaeppeli F. Prolonged parvovirus B19 viremia in spite of neutralizing antibodies after erythema infectiosum in pregnancy. Gynecol Obstet Invest 2007, 63:53-54.
67. Thomas I., Di Giambattista M., Gerard C., et al. Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins. Vox Sang 2003, 84:300-307.
68. Brown K.E., Young N.S., Alving B.M., Barbosa L.H. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001, 41:130-135.
69. Lefrere J.J., Servant-Delmas A., Candotti D., et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 2005, 106:2890-2895.
70. Adamson-Small L.A., Ignatovich I.V., Laemmerhirt M.G., Hobbs J.A. Persistent parvovirus B19 infection in non-erythroid tissues: possible role in the inflammatory and disease process. Virus Res 2014, 190:8-16.
71. Marano G., Vaglio S., Pupella S., et al. Human parvovirus B19 and blood product safety: a tale of twenty years of improvements. Blood Transfus 2015, 13:184-196.
72. Brown K.E., Simmonds P. Parvoviruses and blood transfusion. Transfusion 2007, 47:1745-1750.
73. Kleinman S.H., Glynn S.A., Lee T.H., et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion 2007, 47:1756-1764.
74. Kooistra K., Mesman H.J., de Waal M., Koppelman M.H., Zaaijer H.L. Epidemiology of high-level parvovirus B19 viraemia among Dutch blood donors, 2003-2009. Vox Sang 2011, 100:261-266.
75. Kleinman S.H., Glynn S.A., Lee T.H., et al. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood 2009, 114:3677-3683.
76. Hourfar M.K., Mayr-Wohlfart U., Themann A., et al. Recipients potentially infected with parvovirus B19 by red blood cell products. Transfusion 2011, 51:129-136.
77. Juhl D., Ozdemir M., Dreier J., Gorg S., Hennig H. Look-back study on recipients of parvovirus B19 (B19V) DNA-positive blood components. Vox Sang 2015, 10.1111/vox.12295.
78. Servant-Delmas A., Laperche S., Mercier M., et al. Limits of sequencing and phylogenetic analysis to assess B19V transmission by single-donor blood component. Vox Sang 2011, 100:254-255.
79. Wu C.G., Mason B., Jong J., et al. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion 2005, 45:1003-1010.
80. Allander T., Tammi M.T., Eriksson M., Bjerkner A., Tiveljung-Lindell A., Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 2005, 102:12891-12896.
81. Manning A., Russell V., Eastick K., et al. Epidemiological profile and clinical associations of human bocavirus and other human parvoviruses. J Infect Dis 2006, 194:1283-1290.
82. Jones M.S., Kapoor A., Lukashov V.V., Simmonds P., Hecht F., Delwart E. New DNA viruses identified in patients with acute viral infection syndrome. J Virol 2005, 79:8230-8236.
83. Jartti T., Hedman K., Jartti L., Ruuskanen O., Allander T., Soderlund-Venermo M. Human bocavirus-the first 5 years. Rev Med Virol 2012, 22:46-64.
84. Li X., Kantola K., Hedman L., Arku B., Hedman K., Soderlund-Venermo M. Original antigenic sin with human bocaviruses 1-4. J Gen Virol 2015, 10.1099/jgv.0.000253.
85. Matthews P.C., Malik A., Simmons R., Sharp C., Simmonds P., Klenerman P. PARV4: an emerging tetraparvovirus. PLoS Pathog 2014, 10:e1004036.
86. Servant-Delmas A., Laperche S., Lionnet F., Sharp C., Simmonds P., Lefrere J.J. Human parvovirus 4 infection in low- and high-risk French individuals. Transfusion 2014, 54:744-745.
87. Sharp C.P., Vermeulen M., Nebie Y., et al. Changing epidemiology of human parvovirus 4 infection in sub-Saharan Africa. Emerg Infect Dis 2010, 16:1605-1607.
88. Servant-Delmas A., Laperche S., Mercier M., et al. Human parvovirus 4 in recipients of cellular products and in blood donors: epidemiologic similarity with B19 parvovirus. Transfusion 2009, 49:1771-1773.
89. Maple P.A., Beard S., Parry R.P., Brown K.E. Testing UK blood donors for exposure to human parvovirus 4 using a time-resolved fluorescence immunoassay to screen sera and Western blot to confirm reactive samples. Transfusion 2013, 53:2575-2584.
90. Ma Y.Y., Guo Y., Zhao X., et al. Human parvovirus PARV4 in plasma pools of Chinese origin. Vox Sang 2012, 103:183-185.
91. Bonvicini F., Bua G., Manaresi E., Gallinella G. Antiviral effect of cidofovir on parvovirus B19 replication. Antiviral Res 2015, 113:11-18.
92. Bernstein D.I., El Sahly H.M., Keitel W.A., et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011, 29:7357-7363.